文献速递糖尿病

2型糖尿病患者尿液三羧酸循环代谢物与终末期肾病风险

Urine Tricarboxylic Acid Cycle Metabolites and Risk of End-stage Kidney Disease in Patients With Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

在发现队列(n=1826)和验证队列(n=1235)的2型糖尿病患者中,采用质谱法检测尿液三羧酸循环代谢物。中位随访9.2年和4.0年,分别发生213和107例肾脏事件。Cox回归显示尿延胡索酸和柠檬酸可独立于临床危险因素及其他尿液代谢物预测终末期肾病进展风险。

要点

  • 尿延胡索酸和柠檬酸可独立于临床危险因素预测2型糖尿病患者终末期肾病进展风险。
  • 发现队列中,尿延胡索酸每增加1个标准差,肾脏结局风险增加(aHR 1.82,95%CI 1.17-2.82)。
  • 发现队列中,尿柠檬酸每增加1个标准差,肾脏结局风险降低(aHR 0.83,95%CI 0.72-0.96)。

核心结论

  • 尿延胡索酸和柠檬酸可独立于临床危险因素及其他尿液代谢物预测2型糖尿病患者进展至终末期肾病的风险。

研究设计与样本

  • 前瞻性研究,包括发现队列(n=1826)和验证队列(n=1235),均为2型糖尿病患者,来自一家区域医院和一家初级保健机构。

主要发现

  • 发现队列中位随访9.2年(四分位距8.1-9.7),发生213例肾脏事件;验证队列中位随访4.0年(四分位距3.2-5.1),发生107例肾脏事件。
  • 发现队列中,校正心肾危险因素后,尿乳酸、延胡索酸和苹果酸与肾脏结局风险增加相关(aHR分别为1.63[95%CI 1.16-2.28]、1.82[95%CI 1.17-2.82]和1.49[95%CI 1.05-2.11],均按每标准差计算),而柠檬酸与低风险相关(aHR 0.83[95%CI 0.72-0.96],按每标准差计算)。
  • 上述发现在验证队列中可重复。
  • 进一步校正其他代谢物后,延胡索酸和柠檬酸仍与肾脏结局独立相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Metabolites in the tricarboxylic acid (TCA) pathway have pleiotropic functions. OBJECTIVE: To study the association between urine TCA cycle metabolites and the risk for chronic kidney disease progression in individuals with type 2 diabetes. DESIGN, SETTING AND PARTICIPANTS: A prospective study in a discovery (n = 1826) and a validation (n = 1235) cohort of people with type 2 diabetes in a regional hospital and a primary care facility. EXPOSURE AND OUTCOME: Urine lactate, pyruvate, citrate, alpha-ketoglutarate, succinate, fumarate, and malate were measured by mass spectrometry. Chronic kidney disease progression was defined as a composite of sustained estimated glomerular filtration rate below 15 mL/min/1.73 m2, dialysis, renal death, or doubling of serum creatinine. RESULTS: During a median of 9.2 (interquartile range 8.1-9.7) and 4.0 (3.2-5.1) years of follow-up, 213 and 107 renal events were identified. Cox regression suggested that urine lactate, fumarate, and malate were associated with an increased risk (adjusted hazard ratio, [95% CI] 1.63 [1.16-2.28], 1.82 [1.17-2.82], and 1.49 [1.05-2.11], per SD), whereas citrate was associated with a low risk (aHR 0.83 [0.72-0.96] per SD) for the renal outcome after adjustment for cardiorenal risk factors. These findings were reproducible in the validation cohort. Noteworthy, fumarate and citrate were independently associated with the renal outcome after additional adjustment for other metabolites. CONCLUSION: Urine fumarate and citrate predict the risk for progression to end-stage kidney disease independent of clinical risk factors and other urine metabolites. These 2 metabolites in TCA cycle pathway may play important roles in the pathophysiological network, underpinning progressive loss of kidney function in patients with type 2 diabetes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Liu JJ, Liu S, Zheng H, et al. Urine Tricarboxylic Acid Cycle Metabolites and Risk of End-stage Kidney Disease in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2025. PMID: 38546133. doi:10.1210/clinem/dgae199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。